Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/CAAC.21660

Article  PubMed  Google Scholar 

Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S, Tsuda H (2016) Prognostic impact of discordance in hormone receptor status between primary and recurrent sites in patients with recurrent breast cancer. Clin Breast Cancer 16:e133–e140. https://doi.org/10.1016/J.CLBC.2016.05.014

Article  CAS  PubMed  Google Scholar 

Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905–2919. https://doi.org/10.1093/NAR/29.14.2905

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7:497–508. https://doi.org/10.2174/138920206779315737

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hall J, McDonnell D, Korach K (2002) Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16:469–486. https://doi.org/10.1210/MEND.16.3.0814

Article  CAS  PubMed  Google Scholar 

Levin ER (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951–1959. https://doi.org/10.1210/ME.2004-0390

Article  CAS  PubMed  Google Scholar 

Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89:4658–4662. https://doi.org/10.1073/PNAS.89.10.4658

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA (1993) Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7:992–998. https://doi.org/10.1210/MEND.7.8.8232319

Article  CAS  PubMed  Google Scholar 

Newton CJ, Buric R, Trapp T, Brockmeier S, Pagotto U, Stalla GK (1994) The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol 48:481–486. https://doi.org/10.1016/0960-0760(94)90197-X

Article  CAS  PubMed  Google Scholar 

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817–9824. https://doi.org/10.1074/jbc.M010840200

Article  CAS  PubMed  Google Scholar 

Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE, Stoica A (2000) A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141:4503–4511. https://doi.org/10.1210/ENDO.141.12.7836

Article  CAS  PubMed  Google Scholar 

Cho J, Bahn JJ, Park M, Ahn WS, Lee YJ (2006) Hypoxic activation of unoccupied estrogen-receptor-alpha is mediated by hypoxia-inducible factor-1 alpha. J Steroid Biochem Mol Biol 100:18–23. https://doi.org/10.1016/J.JSBMB.2006.03.002

Article  CAS  PubMed  Google Scholar 

Bennesch MA, Picard D (2015) Minireview: tipping the balance: ligand-independent activation of steroid receptors. Mol Endocrinol 29:349–363. https://doi.org/10.1210/ME.2014-1315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM et al (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21:4921–4931. https://doi.org/10.1038/SJ.ONC.1205420

Article  CAS  PubMed  Google Scholar 

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494. https://doi.org/10.1126/science.270.5241.1491

Article  CAS  PubMed  Google Scholar 

Kim YC, Kim CY, Oh JH, Kim MH (2021) Nr4a1 regulates tamoxifen resistance by suppressing erk signaling in ER-positive breast cancer. Cells 10:1633. https://doi.org/10.3390/CELLS10071633/S1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vafeiadou V, Hany D, Picard D (2022) Hyperactivation of MAPK induces tamoxifen resistance in SPRED2-deficient ERα-positive breast cancer. Cancers 14:954. https://doi.org/10.3390/CANCERS14040954

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Wang N, Fang J, Huang J, Tian F, Li C, Xie F (2012) Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Rep 27:1879–1886. https://doi.org/10.3892/OR.2012.1728

Article  CAS  PubMed  Google Scholar 

Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U (2000) Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer (Pred Oncol) 89:384–388. https://doi.org/10.1002/1097-0215

Article  CAS  Google Scholar 

Bunone G, Briand PA, Miksicek RJ, Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174–2183

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alayev A, Salamon RS, Berger SM, Schwartz NS, Cuesta R, Snyder RB, Holz MK (2016) mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation. Oncogene 35:3535–3543. https://doi.org/10.1038/ONC.2015.414

Article  CAS  PubMed  Google Scholar 

Fritah A, Saucier C, Mester J, Redeuilh G, Sabbah M (2005) p21 WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor α. Mol Cell Biol 25:2419–2430. https://doi.org/10.1128/MCB.25.6.2419-2430.2005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Redeuilh G, Attia A, Mester J, Sabbah M (2002) Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases. Oncogene 21:5773–5782. https://doi.org/10.1038/SJ.ONC.1205753

Article  CAS  PubMed  Google Scholar 

Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C et al (2008) Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 105:288–293. https://doi.org/10.1073/pnas.0710887105

Article  PubMed  Google Scholar 

Schiewer MJ, Knudsen KE (2014) Transcriptional roles of PARP1 in cancer. Mol cancer Res 12:1069–1080. https://doi.org/10.1158/1541-7786.MCR-13-0672

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang F, Wang Y, Wang L, Luo X, Huang K, Wang C, Du M, Liu F, Luo T, Huang D et al (2013) Poly(ADP-ribose) polymerase 1 is a key regulator of estrogen receptor α-dependent gene transcription. J Biol Chem 288:11348–11357. https://doi.org/10.1074/JBC.M112.429134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pulliam N, Tang J, Wang W, Fang F, Sood R, O’Hagan HM, Miller KD, Clarke R, Nephew KP (2019) Poly-ADP-ribosylation of estrogen receptor-alpha by PARP1 mediates antiestrogen resistance in human breast cancer cells. Cancers 11:43. https://doi.org/10.3390/CANCERS11010043

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gadad SS, Camacho CV, Malladi V, Hutti CR, Nagari A, Lee Kraus W (2021) Poly(ADP-ribose) polymerase-1 regulates estrogen-dependent gene expression in estrogen receptor α-positive breast cancer cells. Mol Cancer Res 19:1688–1698. https://doi.org/10.1158/1541-7786.MCR-21-0103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggelis V, Johnston SRD (2019) Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer. Drugs 79:1849–1866. https://doi.org/10.1007/S40265-019-01208-8

Article  CAS  PubMed  Google Scholar 

Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–213. https://doi.org/10.1038/NRD1031

Article  CAS  PubMed  Google Scholar 

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300. https://doi.org/10.1016/S0140-6736(03)12342-2

Article  CAS  PubMed  Google Scholar 

Jankowitz R, Davidson N (2013) Adjuvant endocrine therapy for breast cancer: how long is long enough? Oncology 1224:1210–1216

Google Scholar 

Hultsch S, Kankainen M, Paavolainen L, Kovanen RM, Ikonen E, Kangaspeska S, Pietiäinen V, Kallioniemi O (2018) Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC Cancer 18:1–14. https://doi.org/10.1186/S12885-018-4757-Z

Article  Google Scholar 

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361. https://doi.org/10.1093/JNCI/95.5.353